{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:27:52Z","timestamp":1776310072192,"version":"3.50.1"},"reference-count":30,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"published-print":{"date-parts":[[2005]]},"abstract":"<jats:p>We have investigated the acute and sustained hemodynamic effects of octreotide on hepatic metastases of midgut carcinoids using contrast-enhanced dynamic magnetic resonance imaging (MRI). Seven patients with the carcinoid syndrome and metastasized midgut carcinoid tumors underwent functional dynamic multi-phase gadolinium-enhanced MRI of selected liver metastases at baseline and 60 min after the subcutaneous (s.c.) administration of 100 \u00b5g octreotide, and also after 3 months with three times daily (t.i.d.) 100 \u00b5g octreotide s.c. Baseline MRIs showed the typical aspect of carcinoid liver metastases with a very bright signal on the T2-weighted sequences and intense enhancement in the arterial phase after injection of gadolinium-diethylenetriaminepentaacetate. MRIs 60 min after the s.c. administration of 100 \u00b5g octreotide showed a 34.9 \u00b1 6.2% (mean \u00b1 SD) reduction in relative enhancement in the selected liver metastases as compared to baseline. In 2 patients, however, there was no (significant) reduction in the relative enhancement in the selected liver metastases 60 min after the s.c. administration of 100 \u00b5g octreotide as compared to baseline. Only in 2 patients did the MRIs at 3 months show a decrease in relative enhancement in one of the selected liver metastases. At 3 months, with 100 \u00b5g octreotide s.c. t.i.d., there was no correlation between the change in relative enhancement on MRI and the change in 24-hour 5-HIAA excretion. There is thus only an acute effect of octreotide on the perfusion of liver metastases. This study further shows that contrast-enhanced dynamic MRI can be a very useful tool for studying hemodynamic effects of medical therapies on liver metastases in patients with metastatic midgut carcinoids.<\/jats:p>","DOI":"10.1159\/000090636","type":"journal-article","created":{"date-parts":[[2006,2,7]],"date-time":"2006-02-07T10:08:18Z","timestamp":1139306898000},"page":"41-48","source":"Crossref","is-referenced-by-count":4,"title":["Octreotide Exerts Only Acute, but No Sustained, Effects on MRI Enhancement of Liver Metastases in Carcinoid Syndrome"],"prefix":"10.1159","volume":"82","author":[{"given":"Menno T.","family":"Zomerhuis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid M.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aart-Jan","family":"van der Lely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2006,1,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053%2Fj.gastro.2005.03.038"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2898%2902286-7"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199903183401107"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00259-005-1864-2"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210%2Fjc.2004-1938"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210%2Fer.2002-0007"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdh216"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199601253340408"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159%2F000085237"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.dld.2004.01.028"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136%2Fgut.2004.049031"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2036.2004.02110.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016%2F0002-9343%2886%2990582-6"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2265.2002.01619.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.pharmthera.2004.02.002"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.mric.2005.03.007"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016%2FS0378-4347%2800%2983867-0"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002%2Fjmri.1057"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.rcl.2005.05.006"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1089%2F108497803322287691"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2165%2F00002018-199717050-00004"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210%2Fjc.2005-0260"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016%2F0002-9343%2887%2990426-8"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1067%2Fmge.2001.115336"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053%2Fgast.2001.20892"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016%2FS0168-8278%2897%2980111-0"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1572-0241.2005.41381.x"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjc.6602503"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1530%2Feje.0.1460701"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210%2Fer.2000-0001"}],"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/90636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/90636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:46:26Z","timestamp":1745462786000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000090636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000090636","archive":["Portico"],"relation":{},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}